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Activated macrophages play a central role in controlling inflammatory responses to infection and are tightly
regulated to rapidly mount responses to infectious challenge. Type I interferon (alpha/beta interferon [IFN-
/]) and type II interferon (IFN-) play a crucial role in activating macrophages and subsequently restricting
viral infections. Both types of IFNs signal through related but distinct signaling pathways, inducing a vast
number of interferon-stimulated genes that are overlapping but distinguishable. The exact mechanism by
which IFNs, particularly IFN-, inhibit DNA viruses such as cytomegalovirus (CMV) is still not fully under-
stood. Here, we investigate the antiviral state developed in macrophages upon reversible inhibition of murine
CMV by IFN-. On the basis of molecular profiling of the reversible inhibition, we identify a significant
contribution of a restricted type I IFN subnetwork linked with IFN- activation. Genetic knockout of the type
I-signaling pathway, in the context of IFN- stimulation, revealed an essential requirement for a primed type
I-signaling process in developing a full refractory state in macrophages. A minimal transient induction of
IFN- upon macrophage activation with IFN- is also detectable. In dose and kinetic viral replication
inhibition experiments with IFN-, the establishment of an antiviral effect is demonstrated to occur within the
first hours of infection. We show that the inhibitory mechanisms at these very early times involve a blockade
of the viral major immediate-early promoter activity. Altogether our results show that a primed type I IFN
subnetwork contributes to an immediate-early antiviral state induced by type II IFN activation of macrophages,
with a potential further amplification loop contributed by transient induction of IFN-.
Murine cytomegalovirus (MCMV) infection in mice is a
well-established model system for the study of acute, persis-
tent, and latent infections of betaherpesviruses and their con-
trol by the host immune system (32, 35, 58, 60). Both human
CMV (HCMV) and MCMV infect a broad range of tissues in
their respective hosts, including fibroblasts, endothelial and
epithelial cells, and, significantly, immune cells of the myeloid
lineage (13, 57, 69, 70). Differentiated macrophages of this
lineage residing in infected tissues play a key role in eliciting
the host immune response but are also permissive for CMV
infection and serve as disseminators of the virus throughout
the host (reviewed in reference 29).
In immunocompetent hosts, primary CMV infections are
generally asymptomatic, with immune cells either killing virus-
infected cells or restricting viral cell-to-cell spread and repli-
cation. The latter effect occurs via induction of an antiviral
state in noninfected cells or the activation of immune cells by
soluble mediators such as type I interferon (alpha/beta inter-
feron [IFN-/]) and type II interferon (IFN-) (8, 10, 41, 50,
60, 73). Several hundred genes stimulated in response to both
type I and type II IFNs have been identified by microarrays in
various cell types over the years (18, 19, 37, 38, 66). In contrast,
the recently discovered type III IFNs are not well characterized
but may have comparable functions to the type I IFNs, medi-
ated by shared downstream signaling and IFN-stimulated
genes (ISGs) (3, 33, 42, 63, 72, 78, 84). Type III IFNs are
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predominantly expressed in epithelial cells (72), and in this
regard, activated murine bone marrow-derived macrophages
(BMDMs) showed no induction of type III expression in our
cell system (P. Ghazal, P. Lacaze, and K. A. Robertson, un-
published data). Historically, IFN- and IFN- have been
closely associated with induction of an antiviral state affecting
RNA viruses, while DNA viruses have proven more suscep-
tible to IFN- regulation, which also has an important role
in homeostasis of immune-modulatory functions. The dif-
ferent types of IFNs bind to their cognate receptors, which
activate mainly distinct but related Janus kinase/signal
transducers and activators of transcription (JAK/STAT)-
signaling cascades, resulting in the rapid induction of gene
transcription (11, 74). These distinctions have become in-
creasingly blurred over the years by reports of overlapping
downstream signaling events and cross talk between the type
I-, II-, and III-signaling pathways (25, 52, 55, 67, 68, 78, 85),
demonstrating that the different types of IFNs do not act
absolutely independently.
IFNs suppress viral replication by activating a vast number
of cellular processes with direct and indirect antiviral effects
which render the cell less permissive for viral replication (40,
45, 63). Therefore, determining the precise mechanisms of
viral inhibition by ISGs remains problematic, due to a pleio-
tropic response. In the case of MCMV infection, it has been
demonstrated that IFN- plays a crucial role in modulating the
immune response to infection (6, 30, 31) and in controlling
persistently replicating virus (60). It is known, for example, that
IFN- pretreatment induces an antiviral state in NIH 3T3
fibroblasts by blocking the activity of the major immediate-
early (MIE) promoter (MIEP) (26, 50). Recently, it has been
shown that pretreatment of mouse embryonic fibroblasts
(MEFs) (85) or BMDMs (61) with IFN- also directly estab-
lishes an antiviral state in these cell types. So far the mecha-
nisms underlying this block of MCMV replication in bone
marrow-derived macrophages are not fully understood. It is
notable, however, that the prototypic antiviral effector pro-
teins, such as Mx1, RNase L, or protein kinase R (PKR), do
not seem to play a role in this response, as BMDMs from the
respective knockout (KO) mice were still protected by IFN-
treatment. Interestingly, in the study of Presti et al., this effect
seemed to be independent of type I signaling, as IFN-R1/
BMDMs pretreated with IFN- showed no significant increase
in permissiveness compared to the control cultures (61).
In more recent studies, we have investigated the changes in
the BMDM transcriptome after type II IFN stimulation com-
bined with targeted RNA interference (RNAi) knockdown in
whole-genome microarray experiments (44) and found that an
interferon regulatory factor (IRF)/type I IFN transcriptional
network plays an important role in stimulating ISGs following
IFN- treatment. However, the question of whether a full type
I IFN transcriptional network or subnetwork plays a role in
eliciting an antiviral state in BMDMs after type II IFN stimu-
lation is not clear.
In the present work, we further characterize the type II-
induced antiviral state in BMDMs using a reversible inhibition
approach and now provide evidence for the identification of a
type I IFN subnetwork contributing significantly to the rapid
shutdown of the major immediate-early promoter activity and
establishment of the refractory state in IFN--pretreated
BMDMs in the context of MCMV infection.
MATERIALS AND METHODS
Mice. BALB/c and C57BL/6 (BL6) mice were purchased from Charles River
Laboratories (Kent, United Kingdom) and maintained under specific-pathogen-
free conditions at the University of Edinburgh. Housing and animal procedures
were approved by the United Kingdom Government Home Office. If not indi-
cated differently, BL6 BMDMs have been used for the experiments. Mouse
strains C57BL/6 IFN-R1/, Tyk2/, and IFN-1/ were maintained under
specific-pathogen-free conditions at the Institute of Animal Breeding and Ge-
netics, Department for Biomedical Sciences, University of Veterinary Medicine
Vienna, Vienna, Austria. The generation or source of knockout mouse strains for
IFN-R1/, Tyk2/, and IFN-1/ has been described elsewhere (see ref-
erences 21 and 76 and references therein).
Cells and viruses. Macrophage cultures were established from the bone mar-
row of 10- to 12-week-old male mice as described previously (15, 44). Briefly,
bone marrow progenitors were flushed from femurs and tibias and plated in
tissue culture dishes (Costar; Corning Inc., NY). The cells were cultured in
Dulbecco modified Eagle medium–Ham F-12 medium-glutaMAX medium sup-
plemented with 10% fetal calf serum (FCS), 50 U/ml penicillin and streptomycin,
and 10% L929 conditioned medium as a source of macrophage colony-stimulat-
ing factor (referred to as BMDM growth medium in this report). At 6 days
postisolation, cells had differentiated into mature macrophages, as assessed by
surface expression of Mac-1 and F4/80 markers, and had reached approximately
80% confluence.
MEFs derived from the embryos of timed pregnant C57BL/6 mice on days 14
to 17 of gestation were cultured in Eagle’s minimum essential medium (EMEM)
supplemented with 10% FCS, 50 U/ml penicillin and streptomycin, and 2 mM
glutamine. MEFs were used at passage 3 postisolation for experiments.
The bacterial artificial chromosome (BAC)-derived MCMV strain pSM3fr
(81) (designated MCMV in this report) was used as wild-type (WT) virus.
The Gaussia luciferase (GLuc) reporter virus (GLuc-MCMV) was generated
by site-specific homologous recombination (12, 54, 81). Shortly, the GLuc open
reading frame (ORF), amplified with primers 5-GCGTCTAGAGCCGGCgacg
tcgaagagaacccgggcccgATGGGAGTCAAAGTTCTGTTTG-3 and 5-CTCGAT
ATCTTAGTCACCACCGGCCCCCTTGAT-3 from plasmid pCMV-GLuc
(New England BioLabs), was cloned into pMCMV3 (12, 14), resulting in pm-
MIEP-GLuc. The mCherry ORF amplified with primers 5-GCGAAGCTTAT
GCATGCCGCCATGGTGAGCAAGGGCGAGGA-3 and 5-GTCGCCGGC
ctgcttcaggaggctgaagttcgtggctcccgagccCTTGTACAGCTCGTCCAT-3 from the
template pCMVBrainbow1.1 (49) was inserted into pmMIEP-GLuc, resulting in
pmCherryP2AGLuc. Each of the primer sequences in lowercase letters encodes
one-half of the picornaviral 2A amino acid sequence. Finally, a kanamycin
resistance marker flanked by FLP recombination target sites (12) was inserted,
leading to pmCherryP2AGLucKanR. MCMV BACs were mutated by homolo-
gous recombination in Escherichia coli using the mutagenesis procedure as de-
scribed previously (12). Briefly, PCR fragments were generated using plasmid
pmCherryP2AGLucKanR, and the primers 5-AATCTGAACCCCGATATTT
GAGAAAGTGTACCCCGATATTCAGTACCTCTTCAGGAACACTTAAC
GGCTGA-3 and 5-ACCCGGGCCCTTCACGGTAAGGATCTGACAGTCG
ACCGTCGATTCGTCAGTTTGAATTCGAGCTCGCCCAACTCCG-3. The
50 nucleotides (nt) at the 5 ends of the primers were required for homologous
recombination with the m157 sequence in the MCMV BAC. The PCR product
was electroporated into E. coli containing the BAC pSM3fr (81). Recombined
BACs were characterized by restriction analysis. The kanamycin resistance
marker was subsequently excised by FLP recombinase (12).
For the fluorescent infection assays, BMDMs were infected with a recombi-
nant reporter virus expressing the green fluorescent protein (GFP) marker,
under the control of the HCMV enhancer/promoter, inserted into exon 1 of the
ie2 gene (pSM3fr-rev, called GFP-MCMV in this report and described in detail
elsewhere [1]).
For production of viral stocks, virus strains were propagated on mouse NIH
3T3 cells (ATCC CRL1658) and stocks were prepared as described previously
(58).
IFN- treatment and virus infections. To analyze reversible induction of the
antiviral state by IFN-, macrophage cultures were treated with recombinant
mouse IFN- (biological activity, 9.4  103 U per g; RM200120; Thermo
Scientific) as follows: (i) untreated (IFN-), in which BMDMs were differen-
tiated for 8 days and subsequently used for experiments; (ii) pretreated (IFN-
), in which, on day 7 postculture, cells were prestimulated with 10 U/ml IFN-
(Genetech, Oceanside, CA) for 24 h, after which the medium was removed and
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fresh BMDM growth medium was added; and (iii) pretreated and withdrawn
(w-IFN-), in which, on day 6 postculture, cells were treated with 10 U/ml IFN-
for 24 h. On day 7, the IFN- was removed, and the cells were washed briefly in
medium to remove residual cytokine and incubated in fresh BMDM growth
medium for 24 h. On day 8, cells were used for experiments.
For replication assays in IFN-treated cells or other procedures, BMDMs were
treated on day 6 with 10 U/ml IFN-, if not stated differently, and subsequently
infected as follows.
Infections were basically done as described elsewhere (47). Briefly, infection
was carried out in 	10 to 20% of the initial culture volume, and concentrated
virus suspension was added to achieve a multiplicity of infection (MOI) of 1.
Cells were incubated with viral particles for an adsorption period of 1 h at 37°C
and then washed 3 times with phosphate-buffered saline (PBS). Fresh medium
was added, and cells were further incubated as indicated in the respective ex-
periment.
For viral replication assays, 10% of the total supernatant volume from respec-
tive 6-well cultures was harvested at the indicated time points, and the culture
was replenished with an equal volume of fresh medium. Samples were either
stored at 80°C or analyzed immediately on permissive MEFs by standard
plaque assay (47).
Fluorescent virus infectivity assays. For analysis of reporter expression in
GFP-MCMV-infected BMDMs, cells were analyzed by flow cytometry. BMDMs
were isolated and cultured as described above. On day 5 postisolation, BMDMs
were scraped off and transferred into 24-well tissue culture plates (2  105
cells/well). On day 6, BMDMs were pretreated with IFN- for 24 h and subse-
quently infected (GFP-MCMV; MOI, 1). At 6 h postinfection (p.i.), samples
were scraped off, pelleted by centrifugation, and resuspended in 350 l buffer
(PBS, 1% bovine serum albumin, 1 mM sodium azide).
The prepared samples were analyzed using a Becton Dickinson FACsCalibur
machine (BD Biosciences, Oxford, United Kingdom) and Cellquest Pro soft-
ware, gathering 1  104 detection events (excitation, 488 
 10 nm; detection
filter, 530 nm). Additional data analysis was conducted using Flowjo (version 9.2)
software (Tree Star Inc., Ashland, OR). In all experiments, WT MCMV-infected
BMDMs were used to control for background signal levels produced by auto-
fluorescence of infected BMDMs.
GLuc reporter assay. To measure viral replication or MIEP activity in cells
infected with GLuc-MCMV, BMDMs were pretreated as described and cells
were infected with an MOI of 1. GLuc is efficiently secreted in mammalian cell
systems (82), so cell culture supernatants were harvested and frozen (20°C) at
the indicated time points for later analysis. GLuc activity was measured using the
native form of the GLuc substrate coelenterazine (C-7001; Biosynth, Staad,
Switzerland). Coelenterazine was dissolved in nitrogen-saturated acidified meth-
anol (with 0.1 M HCl) to prepare a stock solution (10 mM) (80). Coelenterazine
work solution (20 nM) was freshly produced by diluting 50 l stock solution 1:500
in PBS–5 M NaCl (nitrogen saturated) and incubating the solution for 30 min
with protection from light. Enzyme activity was measured with a POLARstar
plate reader (BMG Labtech, Offenburg, Germany) in well mode, injecting 50 l
coelenterazine work solution per well and integrating the light signal over a
measurement period of 20 s. Signal intensities of the wells were normalized to
values at 1 s postinjection.
(i) Replication assay. To measure viral replication by GLuc activity, BMDMs
were seeded in 100 l medium (96-well format) and differentiated for 6 days.
Cells were pretreated as described above and infected on day 8. At the indicated
time points, 15 l of culture supernatant was repeatedly harvested and replaced
with fresh medium. Subsequently, 10 l of the samples was used to measure
enzyme activity.
(ii) Synthesis assay. To analyze MIEP activity, BMDMS were prepared as
described above (96-well format) and infected. At the indicated time points, cell
culture supernatant of infected BMDMs was completely removed (100 l) and
replenished with fresh medium. Subsequently, MIEP activity was then analyzed
by measuring enzyme activity in 50 l supernatant.
Real-time reverse transcription-PCR (RT-PCR). To measure the expression
levels of viral immediate-early (IE) genes, the GFP gene, or host candidate
genes, BMDMs were differentiated for 6 days. Cells were treated as described
above and infected (MOI, 1). Total cellular RNA was isolated at 6 h postinfec-
tion (RNeasy minikit; Qiagen, Hilden, Germany), quality controlled, and tran-
scribed into cDNA using an anchored poly(T) primer (Transcriptor first-strand
cDNA synthesis kit; Roche Diagnostics, Burgess Hill, United Kingdom). DNA
templates were diluted 1:10, and changes in viral gene expression levels were
analyzed by relative quantitative real-time PCR using TaqMan primers and
probe combinations as described elsewhere (43, 51). Ready-to-use probe/primer
sets were used to analyze tumor necrosis factor alpha (TNF-) and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) transcript levels (TaqMan gene
expression assay; Applied Biosystems, Carlsbad, CA) as described elsewhere
(44), and PCRs for detecting viral genes were carried out using HotStar Taq
(Qiagen) as recommended by the manufacturer, except for increasing the MgCl2
concentration to 2.5 mM.
Host candidate genes were detected using the Roche Universal Probe Library
(UPL). Gene-specific probe/primer combinations were designed using the Roche
Assay Design Center web application (the UPL probes and primers used in this
study are detailed in Table S5 in the supplemental material).
ET50. The half-maximum (50%) effective pretreatment time (ET50) is basically
identical to the half-maximum (50%) effective or inhibitory concentration (EC50
and IC50, respectively) used to describe the efficiency of inhibitory drugs. There-
fore, ET50 was determined by using an online tool designed to calculate EC50s
(BiodataFit, version 1.02; Chang Bioscience). Viral titers of pretreated and
control BMDM cultures and pretreatment times (n  3) were used to calculate
ET50 values with a best-fit model.
Gene expression profiling. Total cellular RNA was isolated as described pre-
viously (15, 44). Briefly, BMDMs were lysed with TRIzol (Invitrogen, CA) and
the RNA was prepared according to the manufacturer’s instructions. Sample
concentration and purity were measured by spectrophotometry, and RNA integ-
rity was monitored using an Agilent 2100 bioanalyzer system (Agilent, Palo Alto,
CA). Five micrograms of total RNA was converted into double-stranded cDNA
that was then used as a template for T7 RNA polymerase in vitro transcription
in the presence of biotinylated ribonucleotides (Enzo Diagnostics). All proce-
dures were followed according to the manufacturer’s instructions (Affymetrix,
Santa Clara, CA). Fifteen micrograms of each biotinylated cRNA was frag-
mented and hybridized to Affymetrix MG-U74Av2 Genechip microarrays for
18 h and then washed and scanned using a Agilent 2500A scanner according to
the standard protocol. Microarray images were processed using Affymetrix Mi-
croarray Analysis Suite (version 5.0) software.
Microarray data processing and statistical analysis. The numerical data were
processed and analyzed with the Bioconductor package for the R statistical
programming environment (62). Raw data distributions and summary statistics
were assessed for quality. Using the robust multichip average (RMA) algorithm
(36), data were then corrected for background, quantile normalized, and probe
set summarized. Null hypotheses for each gene were based on the comparison
between mock arrays and each of the biological conditions (three independent
biological replicates for each condition) and were tested using an empirical Bayes
moderated t test (71). The false discovery rate associated with simultaneous
testing of multiple genes was controlled using the Benjamini-Hochberg P value
adjustment method (5). Genes were interpreted on the basis of differential
expression between the mock-infected group and each of the two experimental
groups and the corresponding statistical significance. Annotations and functional
classification of gene elements were derived from the Affymetrix NetAffx analysis
center. For cluster analysis of array data, BioLayout Express 3d (23) was used
with a Pearson correlation cutoff of 0.95. To map interferon-induced genes
with the Interferome database (described in reference 64; available at http://www
.interferome.org/search.php), Affymetrix identifiers (IDs) were annotated to
EMBL IDs by using the clone/ID converter (http://idconverter.bioinfo.cnio.es/)
online tool. Functional network and pathway analysis was carried out with the
Ingenuity application (IPA; Ingenuity Systems Inc.) using the fold changes and P
values derived from the statistical analysis described above. IPA dynamically
generates networks of gene, protein, small-molecule, drug, and disease associa-
tions on the basis of hand-curated data held in a proprietary database. To
enhance the explorative interpretation of data, networks are ranked according to
a score calculated via a right-tailed Fisher’s exact test. This test outputs a value
that takes into account the original input gene or proteins of interest and the size
of the network generated. The value enables the application to approximate how
relevant the network is to the analysis. Further information on the computational
methods implemented in IPA can be obtained from Ingenuity Systems Inc.
Microarray data accession number. All microarray data are publicly available
online in the GPX database (http://gpxmea.gti.ed.ac.uk/), microarray data acces-
sion number GPX-00002911, or made available as stated in the respective ref-
erences.
RESULTS
Dose and time dependency of the IFN--induced antiviral
state. To characterize the antiviral effects of IFN- in our
primary BMDM system, we assessed the effect of pretreatment
time on the inhibition of viral replication for IFN- concen-
trations of 1, 10, and 100 U/ml (Fig. 1A). These experiments
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show that pretreatment of BMDMs with IFN- reduces virus
production in replication assays and that virus production
shows a strong dependency on the timing of pretreatment. For
all three concentrations, a pretreatment time of 2 h triggered a
measurable reduction in the numbers of released viral particles
throughout the complete replication assay (Fig. 1A). This
antiviral effect was further enhanced with longer pretreatment
times (4, 6, and 8 h). Incubation with IFN- for 8 h was
sufficient to establish a complete inhibition of viral replication
with 10 and 100 U/ml IFN-, while pretreatment for 6 h sup-
pressed viral replication efficiently so that only a single plaque
developed with 100 U/ml at days 3 and 5 p.i. However, with 10
U/ml IFN and 8 h pretreatment, we could observe a recovery
of replication at day 5, indicating that with this particular
concentration of IFN, the antiviral effect was not sustained for
prolonged incubation periods. Plotting the log10 of the viral
titers at day 4 against the pretreatment time revealed an in-
verse log-linear correlation between viral titers and pretreat-
ment time, with R2 values being0.99 (Fig. 1B). Most notably,
we observed an effective inhibition with all tested IFN- con-
centrations with a pretreatment of less than 2 h. To more
accurately quantify this effect, we determined the ET50s using
a best-fit model of the data shown in Fig. 1B. This analysis
estimated ET50s of 105 min (
13.8 min), 76.85 min (
6.1
min), and 55.75 min (
1.4 min) for 1, 10, and 100 U/ml,
respectively.
From these experiments we conclude that there is a direct
correlation between pretreatment times with IFN- and the
antiviral effect in BMDMs. The detectable lag phase and cal-
culated ET50 values indicate that the inhibitory effect most
likely requires cellular factors that change over time after the
initial stimulus. We also note that the antiviral state is effective
within the first hour of IFN- treatment. In this connection, it
is noteworthy that pretreatment with IFN- does not affect
viral entry (61; P. Ghazal and M. F. Hassim, unpublished
observation).
The antiviral effects of IFN- are dependent on persistent
stimulation. The apparent loss of antiviral activity at late times
after a single treatment is consistent with the well-established
observation that a continuous stimulation with IFN- is necessary
for accumulation of IFN--induced gene products (22, 24).
Therefore, to further assess whether the continuous presence of
IFN- is required to efficiently block viral replication in our ex-
perimental system, different cultures of BMDMs were either con-
tinuously or transiently stimulated with IFN- for 24 h. Cells were
transiently stimulated by incubation with IFN- for 24 h, followed
FIG. 1. Dose and time dependency of the IFN--induced antiviral state. (A) Viral replication was measured by plaque assay in BMDMs that
were pretreated for 2 h, 4 h, 6 h, or 8 h with IFN- or left untreated (0 h) before infection with MCMV (MOI, 1). Cells were pretreated with 1,
10, or 100 U/ml IFN-, as indicated. Dashed lines represent detection limits. Data points located on the x axis represent cultures without detected
plaques; data points on the dashed line indicate cultures with single infection events. If not stated differently, in this and all subsequent figures,
data points depict averages (n  3) and error bars represent SDs. d, days. (B) Correlation of pretreatment time and antiviral effect. Plot of
pretreatment times against viral titers on day 4 showed a log-linear correlation (R2  0.99) for all three IFN- concentrations (1 U/ml, 10 U/ml,
and 100 U/ml). ET50s were calculated by a best-fit model for comparison of plaque numbers of the respective pretreated samples with pretreatment
time.
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by an additional 24-h period in normal medium prior to infec-
tion. As shown in Fig. 2A, the inhibition of the viral repli-
cation induced by the 24-h IFN- pretreatment gradually
diminished following removal of the cytokine stimulus. Al-
though the replication kinetics of the virus infecting the
rested cells were delayed by about 48 h compared to viral
growth kinetics in untreated cells, virus yield gradually in-
creased to levels comparable to those for nontreated cells by
6 days postinfection. In contrast, infected cells cultured in
the continuous presence of IFN- showed a persistent sup-
pression of CMV replication (Fig. 2A). This demonstrates
that the IFN--mediated inhibition of viral replication is
reversible upon withdrawal of the stimulus.
Since the inhibitory effect is detectable at very early times
(Fig. 1B) and the measurement by plaque assays is not
amenable or sensitive enough for detecting early replication
kinetics, we next sought to investigate whether reversible
inhibition by IFN- affects the very early stages of viral
replication. For the purpose of these experiments, we used
a quantitatively more sensitive Gaussia luciferase reporter
virus (GLuc-MCMV) replication assay. In the newly con-
structed GLuc-MCMV, the reporter gene is controlled by
the MIEP element of MCMV and can be utilized to deter-
mine early replication kinetics (Fig. 2B). Importantly, as
shown in Fig. 2C, GLuc-MCMV replication is comparable
to that of MCMV in BMDMs. Accordingly, we used re-
porter virus infection of pretreated BMDMs to assess the
effects of IFN- on the early phase of replication. In con-
trast to the results of the plaque assay, infecting BMDMs
with GLuc-MCMV in the presence of IFN- led to a re-
duced reporter gene expression during the first 48 h of infection
that was partially reversed after removal of IFN- (Fig. 2D). The
results of these experiments reveal that the IFN--induced block-
age of viral replication can also occur at a very early phase of the
infection. As has been speculated by others (61), this could be
caused by a block in MIEP activity.
FIG. 2. The antiviral effects of IFN- are dependent on persistent stimulation. BMDMs were continuously treated with 10 U/ml IFN-
(IFN-; black triangles) or transiently treated (w-IFN-; white circles) or were left untreated (IFN-; black squares); cells were subsequently
infected (MOI, 1). (A) The IFN--induced antiviral state is reversible. BMDMs were pretreated as described and infected at time point 0 with
MCMV. Culture supernatant was analyzed on primary MEFs for secreted infectious virus until the plateau phase for the untreated control was
reached. (B) Schematic representation of the m157 region in wild-type MCMV and mutant reporter virus strain GLuc-MCMV. Reporter gene
expression in the mutant strain is controlled by an additional MCMV MIEP element. Both reporter genes are expressed as one bicistronic mRNA
and autocatalytically cleaved during the translation process by peptide 2A of the foot-and-mouth-disease virus. (C) Replication of both virus strains
in BMDMs is comparable. Viral replication of MCMV (black circles) and GLuc-MCMV (white squares) in BMDMs was measured by standard
plaque assay on primary MEFs and is indistinguishable for both virus strains. (D) Effects of 10 U/ml IFN- pretreatment on viral replication of
GLuc-MCMV are already evident in the first 48 h after infection. Viral replication was monitored by repeated measurement of extracellular levels
of Gaussia luciferase in 10 l culture supernatant. Data points represent means (n  10; error bars are SDs), and the dashed line indicates the
level of the background signal. Symbols are as described for panel A.
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Induction of the antiviral state in BMDMs involves a block-
ade of MIEP activity. In the initial report of an IFN--induced
antiviral state in BMDMs by Presti et al. (61), a reduction in
IE1 protein and mRNA levels in IFN--treated cells which was
not attributable to differences in the amount of virus uptake
was demonstrated. Significantly, however, it is not known
whether a reduced promoter activity or a specifically targeted
degradation of viral transcripts is responsible for the antiviral
phenotype. With this in mind and to further investigate
whether the IE phase of viral infection is susceptible to IFN-
control, we analyzed the GLuc expression during the immedi-
ate-early and early phases of the infection cycle. In these ex-
periments, BMDMs were infected with GLuc-MCMV (MOI,
1) and GLuc activity in the culture was measured for the first
8 h p.i. Figure 3A shows strongly reduced reporter gene ex-
pression in the IFN--treated cultures. In agreement with the
reporter gene expression in the replication assay (Fig. 2D), we
detected increased reporter gene levels in cultures that were
rested for 24 h after removing IFN-. The levels of GLuc
activity in the rested cultures did not reach the levels of the
mock-treated culture, supporting the proposed partial relief of
the blockage.
It is possible that the reporter system used in these assays does
not represent the endogenous MIEP activity. To determine if the
measurement of the reduced reporter gene levels in our system
accurately reflects MIEP activity, we concurrently measured the
endogenous viral major immediate early (MIE) gene expression
in GLuc-MCMV-infected cells. In these experiments, we com-
pared mRNA levels of the viral MIE transcripts by relative quan-
titative two-step RT-PCR between the different conditions (Fig.
3B). Oligo(dT) primers were used to produce cDNA from poly-
adenylated transcripts, and the cellular marker gene GAPDH was
used to normalize expression levels of viral MIE gene transcripts.
Notably, viral ie1, ie2, and ie3 cDNAs were less abundant in
FIG. 3. Establishing an antiviral state in BMDMs involves a blockage of MIEP activity. (A) The inhibitory effect of IFN- is already evident
in the immediate-early phase of viral replication. MIEP activity was measured by GLuc synthesis assay. BMDMs that were continuously treated
with 10 U/ml IFN- (IFN-; black triangles), transiently treated (w-IFN-; white circles), or untreated (IFN-; black squares) were infected
with GLuc-MCMV (MOI, 1). GLuc activity released into cell culture supernatant was measured in 2-h time windows, and supernatant was
completely replaced at each indicated sampling point. Data points represent means (n  6; error bars are SDs), with the dashed line indicating
the level of the background signal. (B) IFN- treatment reversibly inhibits expression of the viral major IE genes. Relative comparison of mRNA
levels of MIE genes by quantitative real-time PCR. BMDMs were pretreated and infected as described for panel A. Total cell cDNA was analyzed
with intron-spanning MIE gene-specific TaqMan probes and compared to that from untreated samples. Cellular GAPDH mRNA was used for
normalization. Bars represent mean relative quantification values of 3 independent biological replicates (error bars depict SEMs). (C) Measure-
ment of reporter expression in individual cells. Flow cytometry side scatter and GFP fluorescence dot plots of GFP-positive gated BMDM
populations (dot plots of complete populations are available in Fig. S4 in the supplemental material). Cells pretreated with the indicated IFN-
concentrations for 24 h and subsequently infected (MOI, 1) with GFP-MCMV were harvested at 6 h p.i., and 10,000 cells for respective treatments
were analyzed for GFP expression. Autofluorescence of BMDMs infected with MCMV was used to define the threshold for the GFP gate.
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IFN--treated cells than in rested cells. This observation was in
concordance with the previously observed reversible blockade of
reporter gene expression.
To control if the observed effects on viral MIEP and re-
porter gene expression are restricted to the GLuc-MCMV
system, we used a second, distinct reporter virus (1) carrying
the GFP gene under the control of the functionally homolo-
gous HCMV enhancer/promoter (2) inserted into the first
exon of the ie2 gene in the MCMV genome (GFP-MCMV).
We analyzed the effects of three IFN- concentrations (0.1, 1,
and 10 U/ml) on IE1, IE3, and GFP mRNA levels by quanti-
tative RT-PCR (qRT-PCR) (see Fig. S1 in the supplemental
material). The levels of IE mRNAs were quantitatively re-
duced to a similar extent as the GFP mRNA. The observed
reduction in GFP expression also demonstrates that the inhib-
itory effects of IFN- are not restricted to the GLuc reporter
virus. The fact that the genetic locus carrying the reporter
genes differs among the different reporter viruses further indi-
cates that the reduced expression levels are not caused by any
position-related effects and that the MIEP blockage is not
acting exclusively on the MCMV enhancer but also affects the
HCMV enhancer.
The reporter gene assays and the analysis of the transcript
levels described above indicate that the pretreatment with
IFN- reduces MIEP activity in BMDMs. Significantly, both
assays yield an ensemble measurement of the cell culture sam-
ples. In other words, these experiments represent an average
measurement of the entire population of cells and do not
distinguish between a general population effect and a potential
reduction in only a subset of the population of infected cells.
For this reason, we next sought to analyze the cell frequency
distribution of MIEP activity in our cell culture system using
the GFP-tagged reporter virus (1). Pretreated BMDMs were
infected, and GFP levels in the infected cells were measured by
flow cytometry. This assay shows a strong reduction in the
number of GFP-positive cells as well as a drop in the number
of highly fluorescent cells, as demonstrated by the dot plots
of GFP fluorescence level per cell of the gated population
(Fig. 3C).
Altogether these experiments provide multiple lines of evi-
dence showing that pretreatment with IFN- induces a block-
ade of viral replication which is already evident at the level of
MIEP activity. Moreover, the different reporter and endoge-
nous mRNA expression assays demonstrate that the antiviral
mechanism is not specifically targeting the MIE mRNAs of
MCMV but does influence the activity of the MIE promoter/
enhancer element controlling the expression of the essential
viral MIE gene locus.
It is also noteworthy that these results further indicate that
the IFN--inhibitory effect of MCMV in BMDMs involves
partially reversible inhibition of the MIEP activity and viral
replication, suggesting that both nonreversibly and reversibly
stimulated cellular factors (ISGs) can influence the IFN--
induced antiviral state.
Analysis of gene transcript profiles in BMDMs reversibly
treated with IFN- and identification of candidate genes
underlying the reversible antiviral state in BMDMs. As the
antiviral state is partially reversible, we assume that cellular
gene products involved in establishing this state are regulated
correspondingly. Thus, to investigate the cellular changes as-
sociated with the reversible and the nonreversible refractory
state, we performed microarray analysis (GPX accession num-
ber for data set, GPX-000029.1) of cellular gene expression
levels in IFN--pretreated BMDMs and BMDMs after IFN-
withdrawal. In these experiments, total RNA samples were
labeled and hybridized to murine genome MG-U74Av2 arrays
(Affymetrix). Approximately 50% of the total number of
probes present on the arrays fulfilled these criteria and were
considered detected in the experiment: 6,231 (mock treated),
5,903 (IFN-), and 6,081 (w-IFN-) probes produced a de-
tectable signal with the indicated samples.
For the purpose of this investigation, we first focused our
analysis on genes whose expression is differentially upregulated
by IFN- treatment (i.e., ISGs). On this basis, a comparison of
the 24-h IFN- data set with the mock-treated control iden-
tified 521 targets that were strongly induced (the full gene list
is available in Table S1 in the supplemental material). This is
in good accordance with the 511 IFN--induced genes re-
ported by others (37). Next, the 521 identified IFN-stimulated
probe set was further subjected to cluster analysis with Bio-
Layout Express3d. Using a Pearson correlation cutoff of 0.95
produced 5 clusters of coregulated genes (Fig. 4A), with 33
targets having values below the cutoff and 18 targets being
excluded from further analysis due to incomplete annotation.
Clusters 1 and 2 contain 405 genes that are induced by IFN-
and seemed to return to the baseline level of expression in the
samples when IFN- was withdrawn (Fig. 4A, blue-shaded
clusters); clusters 3 and 4 contain 49 genes that were induced
but maintained an elevated expression level after IFN- with-
drawal (red-shaded clusters). The last cluster consists of 16
genes that were induced by IFN- and showed no reduction in
expression levels (green cluster) in the samples after with-
drawal of IFN- (w-IFN-). As shown in Fig. 2 and Fig. 3, the
IFN--induced antiviral state in BMDMs is partially reversible
by removing IFN- from the culture. Under these reversible
conditions, underlying candidate genes would be expected to
be expressed correspondingly. To more precisely identify can-
didate genes in the groups for the reversible and the nonre-
versible phenotypes, we applied a more stringent statistical
testing (eBayes test, with P  0.05), comparing expression
levels in the w-IFN- samples with those in the mock-treated
samples and accepting only targets for the reversible pheno-
type that were not significantly upregulated in the w-IFN-
samples in comparison to the mock-treated samples. This anal-
ysis identified 163 targets (group A in Fig. 4B) that were
induced compared to the mock-treated control in the 24-h
IFN- data set but showed no significant difference between
the mock treatment and the w-IFN- data sets. This demon-
strates that this group of genes is dependent on a continuous
stimulation with IFN- for regulation. In contrast to this, 358
genes (group B) showed an elevated expression level compared
to that for the mock treatment after withdrawal of IFN- and
therefore formed the group of candidate genes for the nonre-
versible component of the MIEP blockage.
To identify canonical pathways and functional networks in
these groups, we used the Ingenuity pathway analysis tool. The
analysis emphasized the pleiotropic cellular response to IFN-
treatment, with 	200 canonical pathways and 65 functional
networks being associated with the IFN--induced genes. As
expected, we found high correlations between our input genes
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and networks related to the inflammatory response, antigen
presentation, cellular development, and cell signaling. Notably,
networks related to cellular movement, cell-to-cell signaling
and interactions, cell death, lipid metabolism, and molecular
transport were also found to be associated with our candidate
genes (summarized in Table S4 in the supplemental material).
In this connection, we have recently shown that genes involved
in sterol biosynthesis contribute to the antiviral state at late
times of infection, showing that continuous exposure to IFN-
is necessary to sustain the reduction in cholesterol biosynthesis
(9). Significantly, we found that most networks had members
drawn from both the reversible and nonreversible gene sets.
Notably, however, some networks, e.g., the functional network
for antigen presentation, had a stronger correlation with genes
that maintained an elevated expression level (49 common
genes; P  6.5  1011), while the functional network for gene
expression was stronger correlated to the reversibly induced
genes (48 common genes; P  9.1  1010).
This microarray analysis provides candidate gene lists and
functional networks for the mechanistic analysis of the IFN--
induced antiviral effect in BMDMs. A more in-depth analysis
and functional systematic screening of candidate genes will be
undertaken in future investigations.
Type I IFN-responsive genes constitute a part of the IFN-
-induced transcriptional changes in BMDMs. In the various
gene sets associated with the reversible inhibition, there is a
striking type I IFN-related component detectable. Analysis of
the 163 transiently induced targets identified a group of can-
didates that have been described to be induced specifically by
type I signaling (18), i.e., Mx1/2, Ifit2 (IFI-54K), Ifih1 (MDA-5),
and Ifitm3 (48). Furthermore, comparison of the group of 163
transiently induced candidate genes (group A) with the se-
FIG. 4. Analysis of gene transcription profiles in BMDMs treated with IFN-. BMDMs (BALB/c) were treated with IFN- (3 replicates) as
described (IFN- or w-IFN-) or left untreated (IFN-). Statistical analysis of the array data (GPX accession number GPX-000029.1) then
identified 521 probes whose expression was significantly altered. (A) Cluster analysis of the 521 identified targets. Expression profiles of the 521
targets over the three conditions were compared, and a Pearson correlation of 0.95 was used as the cutoff for cluster formation. Profiles grouped
into five clusters (clusters C1 to C5), indicated in the corresponding line plots, which show the average expression profile of the corresponding
clusters over the three conditions (right). Gene numbers in the groups are shown in parentheses. In the network representation of the clustering
(A), gray nodes represent 33 probe sets that were below the cutoff for clustering, and 18 probes were excluded due to incomplete annotation.
(B) Heat map of the 521 identified targets with three replicates for each condition (continuously numbered). Expression levels were normalized
to the average of the data set. Statistical testing (empirical Bayes test) was used to filter for genes that reversed expression levels completely after
withdrawal of IFN-. One hundred sixty-three targets which fulfilled the criteria were identified (P  0.05). The heat map was produced using
supervised clustering, which organized 163 targets into group A and the remaining 358 targets into group B. (C) Type I IFN-induced genes form
a substantial part of the induced transcriptional network. Probe sets were mapped to a nonredundant list of ENSEMBL identifiers, resulting in
492 discrete candidates for further analysis. This list was used to query the Interferome database to identify genes specifically induced by type I
IFNs. For the 154 ENSEMBL identifiers from group A, 27 genes were specifically induced by type I IFNs (I), 38 genes were induced by type I or
type II IFNs (I/II), and 89 genes could not be mapped to the database. (D) IFN- influences basal and induced expression levels of candidate host
genes in the IFN- BMDM system. Genes of group A were compared to array data from BMDMs transfected with control siRNAs (RISC) or an
siRNA targeting IFN- and subsequently treated with IFN- (44). (Left) Average microarray expression data (n  3) for five exemplary target
genes; (right) qRT-PCR data for the same set of genes in WT and IFN-1/ BMDMs after treatment with 10 U/ml IFN-. A complete list of
target genes and expression levels for the microarray and qRT-PCR data set are available (see Table S3 and Fig. S2 in the supplemental material).
VOL. 85, 2011 IFN--INDUCED REVERSIBLE ANTIVIRAL STATE IN BMDMs 10293
 o
n
 N
ovem
ber 9, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
quences in the Interferome database (64) showed a significant
number of genes (Fig. 4C) that have been demonstrated to be
specifically induced by type I IFNs (27 of 65 mapped genes) or
by both type I and type II IFNs (38 of 65 mapped genes), while
89 genes of group A could not be mapped to the database (a
summary of the analysis is provided in Table S2 in the supple-
mental material). Although a significantly smaller number of
the 358 genes could be mapped to sequences in the Interfer-
ome database, the analysis of the mapped genes of group B
gave comparable results (see Table S2 in the supplemental
material).
IFN- influences the expression levels of the induced can-
didate genes. The fact that we observed the expression of genes
that are typically induced by type I IFNs raised the question of
whether the expression of these genes represented an overlap
between the type I and type II responses or whether there
might be a more direct functional involvement of type I IFN
signaling. We therefore assessed if the type I-signaling pathway
is directly involved in the IFN--induced phenotype in our
experimental system. As shown in Fig. 2, the antiviral effects of
IFN- pretreatment are reversible and, therefore, dependent
on a continuous stimulation with IFN-. Figure 4A and B
demonstrates that the 163 targets in group A show a depen-
dency on IFN- for the maintenance of their expression pro-
files. To extend our understanding of type I IFN-signaling in
this system, we compared the expression levels of our 163
induced targets with those from a microarray data set from our
previous study (44). Data from a representative group of these
genes is presented in Fig. 4D, left (the full data set is available
in Table S3 in the supplemental material). In BMDMs with a
small interfering RNA (siRNA)-mediated knockdown of
IFN-, more than 50% of the targets identified in our study
showed reduced expression levels compared to cells treated
with a control siRNA (RNA-induced silencing complex [RISC]
free) after stimulation with IFN-. These results indicate that
the induction of the target genes by IFN- is dependent on
IFN- expression. Next, we extended the comparison of our
163 targets to STAT1 and STAT2 knockdown experiments
(44) and found comparable results.
The above study points to either a priming of BMDM cul-
tures by type I IFNs or an increased expression due to the
induction of an autocrine IFN- feedback loop. To further
evaluate the involvement of IFN-, we next measured the
relative expression levels of selected candidate genes in IFN-
-treated BMDMs from WT and IFN-1/ mice by qRT-
PCR (Fig. 4D, right; the full data set is available in Fig. S2 in
the supplemental material). In these experiments, most of the
tested candidate genes showed an already reduced expression
level in IFN-1/ mock-treated cultures, supportive for a
priming of BMDM cultures by type I IFNs. In addition to this,
expression levels of the candidate genes were also less respon-
sive to IFN- treatment in IFN-1/ cells than WT cells.
Altogether these experiments suggest that approximately 50%
of our candidate gene list is dependent on a primed type I IFN
signaling, potentially with an additional inducible amplifier
feedback loop.
Type I IFNs play a functional role in establishing the IFN-
-induced antiviral state. Analysis of the data obtained so far
indicated a contribution of the type I IFN system to the estab-
lishment of the type II-induced antiviral state in BMDMs that
is most likely due to a priming effect of the type I IFN-signaling
pathway. However, the question of whether an IFN- stimulus
directly induces type I IFN expression in our system remains
open.
In order to examine this question, we first considered from
microarray experiments changes in IFN- expression levels in
BMDMs treated with IFN- over a period of 12 h (9). This
analysis showed a transient and relatively small, 	4-fold, in-
crease in IFN- expression between 4 h and 6 h after the
stimulus (Fig. 5A). Notably, we did not detect any changes in
expression levels of several members of the IFN- gene family
or IFN- (see Fig. S3 in the supplemental material). Probes
detecting type III interferons were not present on this array,
but in other microarray studies, we found no detectable in-
crease of abundance of type III IFNs (interleukin-28a/b; K. A.
Robertson and P. Ghazal, unpublished observation). To ex-
plore whether this increase in RNA levels was accompanied by
a measurable increase in levels of secreted IFN-, we pro-
ceeded to analyze cell culture supernatants from IFN--
treated BMDMs using an IFN--specific enzyme-linked immu-
nosorbent assay (ELISA). As shown in Fig. 5B, we were able to
detect small amounts of IFN- in the cell cultures, with levels
rising to 40 pg/ml from 6 h after IFN- treatment, just at the
limit of detection of our assay. The increase is slightly delayed
from the increase in RNA levels, which is to be expected. In
contrast to this observation, infected control cultures produced
up to 1,000 pg/ml IFN- (data not shown). This result indicates
the possibility that a potential autocrine amplifier loop cannot
be excluded from contributing to the antiviral state by transient
induction of IFN-.
Ability of IFN- to inhibit release of viral particles is af-
fected by impaired type I IFN signaling. To clarify if the type
I IFNs contribute to the antiviral state in direct functional
assays, we used systems with impaired type I IFN-signaling
pathways for further analysis. In experiments to test if type I
signaling plays a role in the inhibition of MCMV replication,
we analyzed viral infection of BMDMs derived from homozy-
gous genetic IFN-R1/ and Tyk2/ mice and compared
this with infection of WT BMDMs on days 3 and 5 postinfec-
tion. The number of infectious particles in a cell culture su-
pernatant of infected BMDMs was measured by standard
plaque assay on MEFs. It is known that BMDMs of type I-KO
mice are more susceptible for MCMV replication (76); there-
fore, ratios between IFN--pretreated and untreated cultures
were calculated to allow comparison between the different KO
systems. Relative efficiencies of plaque formation were calcu-
lated by comparing mean values for plaque numbers in the
IFN--treated samples with those in the respective mock-
treated BMDMs for each genetic background at each time
point (Fig. 5C).
It has been proposed that type I receptors colocalize with
type II receptors, and therefore, the deletion of IFN-R1
could impair type II signaling by influencing receptor
dimerization (77). To control for this, we included BMDMs
from Tyk2/ mice in our analysis. In these cells, IFN-R1
levels are comparable to those in WT BMDMs (39), but
downstream signaling events of the type I IFN signaling are
reduced. Pretreatment of BMDMs from both types of
knockout mice with IFN- reduced the efficiency of plaque
formation to a lesser extent than in wild-type BMDMs,
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demonstrating that IFN-R1 and the downstream type I
signaling are necessary to fully establish an antiviral state by
IFN- treatment.
The block of MIEP activity is reduced in BMDMs with
impaired IFN signaling. Our analysis of IFN- effects on re-
porter gene expression suggests that a part of the mechanism
of IFN--induced antiviral activity involved a blockade of
MIEP activity (Fig. 3). To investigate if the functionality of the
type I-signaling pathway is necessary for this blockade, we
analyzed normalized GFP reporter gene expression in
BMDMs derived from IFN-R1/, IFN-1/, and STAT1/
mice. As shown in Fig. 5D, dose-dependent inhibition of GFP
expression by IFN- and, therefore, MIEP activity showed an
absolute dependency on STAT1 and a partial dependency on
type I signaling. Deletion of the type I receptor IFN-R1 had
a strong effect, leading to higher levels of GFP than in wild-
type BMDMs after IFN- pretreatment and infection. Signif-
icantly, deletion of the IFN-1 gene also increased the GFP
expression, demonstrating that the contribution of type I IFNs
to the MIEP blockage is dependent on IFN secretion and is
not restricted to a cytoplasmic cross talk between the type I
and type II-signaling pathways alone. However, inhibition by
IFN- is less effective in the IFN-R1/ BMDMs than the
IFN-1/ BMDMs. It is likely that members of the IFN-
gene family also play a role and can partially compensate for
the loss of IFN-. Furthermore, the difference in GFP levels
between WT BMDMs and the type I-deficient BMDMs was
smaller for higher IFN- concentrations, indicating that
high doses of IFN- can compensate for a loss of type I
signaling. Overall, the above work demonstrates that the
involvement of type I IFNs is necessary for the establish-
ment of a full IFN--induced blockade of MIEP activity.
Further, when low, arguably physiologically more relevant
doses of IFN- were analyzed, we found that small quanti-
ties of type I IFNs are sufficient to develop a full IFN--
induced antiviral response.
FIG. 5. Type I IFNs play a functional role in establishing the IFN--induced antiviral state. (A) Low levels of IFN- mRNA transcription are
induced by IFN- stimulation. Normalized IFN- expression levels were derived from an Agilent V2 array with cDNA from IFN--treated
BMDMs (BALB/c). Total cellular RNA was sampled at the indicated time points, and the derived cDNA was analyzed by whole-genome
microarray, as described in reference 9. (B) Minimal IFN- secretion is induced in IFN--treated cells. The concentration of IFN- in supernatants
of IFN- (10 U/ml)-treated BMDM cultures from BALB/c mice was measured by ELISA (white rhombs). Supernatant from mock-treated cultures
was used as a negative control (black rhombs). (C) Type I IFNs contribute to the IFN--induced antiviral state in BMDMs. Plaque assay measuring
viral replication in BMDMs pretreated with IFN-. BMDMs from wild type, IFN-R1/, or Tyk2/ mice were pretreated with 10 U/ml IFN-
and infected with MCMV (MOI, 1). Relative plaque formation was calculated at each indicated time point from means of treated and untreated
samples. Error bars depict SDs of the ratios. We used the delta method (17) as an approximation to obtain an error estimate for the calculated
ratio of treated over untreated. The estimate is calculated under the assumption that the two variables are normally distributed, independent, and
not correlated. (D) Type I IFNs contribute to the IFN--induced block of viral IE gene expression. BMDMs from wild type, IFN-1/,
IFN-R1/, or STAT1/ mice were pretreated with IFN- and subsequently infected with GFP-MCMV (MOI, 1). Cells were fixed at 6 h p.i.
and analyzed by flow cytometry for GFP expression.
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DISCUSSION
In this paper we have investigated the antiviral effects of
IFN- on the MCMV transcription-replication cycle in primary
BMDMs. We demonstrate that the IFN- effect is a rapidly
initiated process within the first hour of stimulus exposure that
increases during the first 8 h of pretreatment and is triggered
by doses of IFN- as low as 1 U/ml. The antiviral effects of
IFN- may be reversed by resting cells for 24 h after the
removal of IFN-. This raises the notion of a select temporal
window for effective control of infection by IFN-, with impor-
tant implications for in vivo acute and latent infections. Mech-
anistically, we further demonstrate that pretreatment of
BMDMs with IFN- alters the level of MIE gene transcription
controlled by the MIEP. Finally, we identified clusters of cel-
lular candidate genes of potential importance to the above
observations by analyzing their expression profiles and found
that the type I IFN-signaling pathway is functionally important
to the antiviral effects of IFN-.
It is now well established that IFN- is an important antiviral
factor which controls in vivo MCMV replication and disease (7,
31, 41, 60, 73). More recently, it was described that the pre-
treatment of primary cells, i.e., BMDMs and MEFs, with
IFN- renders these cell types less susceptible to MCMV in-
fection. This effect was stronger in BMDMs than in MEFs, was
absolutely dependent on STAT1 function, and proved to be
independent of the genes for the cellular effectors PKR,
RNase L, and inducible nitric oxide synthase. Notably, in the
study of Presti et al. (61), the signaling molecules TNF- and
type I IFNs (IFN-/) did not play a significant role in eliciting
the antiviral effect in BMDMs derived from the corresponding
receptor-knockout mice. From a mechanistic perspective, the
IFN- pretreatment of BMDMs led to reduced levels of viral
ie1, e1, m54, and gB mRNAs and IE1 and E1 protein levels
(61). In accordance with this report, we now show that IFN-
pretreatment directly affects the transcriptional activity of the
MIEP. We are aware that this represents only a part of the
whole multifactorial IFN- antiviral response. In this connec-
tion, we have recently shown that IFN--mediated inhibition of
MCMV replication in BMDMs involves the reduction of the
sterol biosynthesis pathway (9) at later times of infection (ini-
tiated at 6 h p.i., with a maximal effect at 24 h p.i.).
It is well-known that the IFN- effect involves induction of
gene transcription and protein synthesis, and our results indi-
cate that the antiviral state involves rapidly induced transcrip-
tion of cellular factors that are active at as early as 1 to 2 h
posttreatment and accumulate during the next few hours. We
have described the very early effects (within the first hour) of
IFN- stimulation on NIH 3T3 cells (20). In this regard, others
have also reported IFN--mediated inhibition of MCMV in
NIH 3T3 fibroblasts at very early times of infection. However,
this was associated with reduced MIE gene transcription by
high doses of IFN- or IFN- (1,000 inhibitory units/ml) in
reporter plasmids (26) and was reported to be due to down-
regulation of NF-B (27). However, the role for NF-B in
inhibition or activation of the viral MIEP in infected cultures is
controversial (4, 28).
A similar observation has also been made in BMDMs, where
inhibition of the virus was associated with reduced levels of IE1
and E1 mRNA and protein (61). In this study, we confirmed
these findings in BMDMs and added further evidence for a
blockade of viral promoter activity comparable to reported
IFN- effects in the NIH 3T3 fibroblast system. Significantly, a
quantitative real-time PCR analysis of MIE mRNA levels in
IFN--treated cultures demonstrated that these transcripts
were reduced in abundance compared to mock-treated cul-
tures. The use of different reporter viruses demonstrated, fur-
thermore, that this effect was most likely caused by a reduced
MIEP activity and not by a sequence-specific degradation of
viral MIEP mRNAs by, e.g., antiviral host micro-RNAs (46,
65). This demonstrates that in BMDMs, the refractory state is
associated with a reduced expression of the essential viral MIE
genes, which are crucial to the initiation of the viral replication
cycle (1, 53).
We have further demonstrated, for the first time, a revers-
ible IFN--induced blockade of the viral transcription-replica-
tion cycle. Significantly, our results show that the reversible
phenotype coincides with a restoration of MIEP activity. No-
tably, however, in contrast to the plaque numbers, the MIEP
activity showed only a partial recovery. In relation to this ob-
servation, it has recently been described that reduced MIEP
activity is sufficient to sustain viral replication in vitro and in
vivo (43, 59). This observation could explain our observed
differences in the levels of inhibition between MIEP activity
and release of viral particles, where reduced MIEP activity
appears to be sufficient to maintain viral replication in our
system. These results raise the possibility that the blockage of
MIEP activity is multifactorial and may comprise a component
whose activity is independent of continuous IFN- stimulation
and another component whose activity is reversible and depen-
dent on the continuous presence of IFN-.
Alongside its ability to directly block viral replication, IFN-
also plays an important role as a link between the innate and
adaptive immune responses (8, 11, 67). It has been demon-
strated that the innate immune response is capable of limiting
CMV during the first week of infection. Significantly, however,
without a functional adaptive immune response, the virus
eventually overcomes this control (31, 50, 56). The reversible
block of MIEP activity described here may provide a temporal
window of opportunity for CMV to escape the innate immune
response when levels of IFN activity drop.
IFNs induce a pleiotropic response in cells and upregulate
the expression of hundreds of genes (18, 19, 37). In this study,
we have exploited a reversible IFN--induced refractory state
to identify candidate genes with potential antiviral functions at
early times of infection. We applied a pathway analysis of the
nonreversibly and reversibly induced genes for enrichment of
functional networks. In the group of the reversibly induced
host factors, we found an enrichment of networks strongly
associated with regulators of the IFN pathway, signaling mol-
ecules, as well as some effector genes. Notably, analysis of the
candidate genes identified a group of genes that have been
described to be exclusively IFN type I specific (18, 48).
Type I IFNs are known to effectively inhibit MCMV repli-
cation in NIH 3T3 cells and BMDMs (26, 76). It is noteworthy
that in our study we did not observe a prototypic type I re-
sponse involving antiviral factors such as PKR, RNase L, ISG-
15, or oligoadenylate synthetase. This is in agreement with the
study of Presti and colleagues, where corresponding cells from
knockout mice showed no significant differences in permissive-
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ness (61). Instead, we identified a type I subnetwork consisting
of upregulated members of the tripartite motif (TRIM) family,
Ifit2 (ISG-54K), Ifih1 (MDA-5), and Ifitm3. In addition, we
detected small quantities of transiently induced IFN- protein
in cultures at about 6 h after treatment with IFN-. These
results are somewhat contradictory to a report from Costa-
Pereira and colleagues (16), who found no induction of type I
IFNs by IFN-. Significantly, however, in that study, human
U5A cells were used and the divergent results probably reflect
differences between experimental systems. In support of this
conclusion, others have reported the induction of type I IFNs
by IFN- in mouse macrophages (83).
Notably, analysis of expression levels of host candidate genes
in IFN-1/ cells by qRT-PCR demonstrated that these
genes were dependent on type I IFNs either to maintain their
basal expression levels or to fully respond to the IFN- stim-
ulus. Taken together, this demonstrates that priming of cells
with a potential restricted autocrine type I IFN loop plays an
important role in establishing the antiviral effects of IFN-
(Fig. 3D and schematically shown in Fig. 6).
In agreement with this, we observed in this study the induc-
tion of MDA-5, TANK, TBK1, STAT1, IFN-R2, IRF1, IRF8,
and IRF7 in IFN--treated samples. These are factors typically
involved in type I-signaling cascades (34) and would, therefore,
increase the sensitivity of the type I amplifier loop as well as
prime the system for other type I IFN-inducing factors. Our
current results and prior siRNA-knockdown studies demon-
strate that the IFN--induced antiviral state in BMDMs is not
independent of IFN type I activity and that disruption of IFN-
expression or function reduces the effects of IFN-. These
results seemingly contradict those from the study of Presti et
al. (61), who found no dependence of IFN--mediated effects
on type I IFNs in IFN-R1/ BMDMs. However, it is notable
that Presti and colleagues used 100 U/ml of IFN- for 48 h to
pretreat BMDMs (61). As we have demonstrated in this study,
the dependence on type I IFNs becomes especially relevant at
low concentrations of IFN- (lower than 10 U/ml) because
higher IFN- levels seem to compensate for the loss of the type
I function. Therefore, our results do not necessarily contradict
those from the study of Presti et al. (61) but extend their
findings to lower and presumably more physiological concen-
trations of IFN-.
Interestingly, in our gene expression experiments we found
no induction of other type I IFNs, although IFN- transcripts
were detectable at low levels at all time points but did not
increase in abundance following IFN- stimulation. Interest-
ingly, IFN- cytokines have their own set of receptors but share
downstream signaling elements with type I IFNs, inducing a
type I-like response (42, 78, 84). In this regard, we note that a
recent publication demonstrated that IFN- production is cell
specific and that this cytokine acts predominantly on epithelial
cells (72). The array platform that we used contained no
probes directed against type III IFNs; however, we did not
detect any differential expression of type III IFNs in other
microarray experiments in our cell system (Robertson and
Ghazal, unpublished).
Despite the fact that we could not detect expression of the
typical type I-induced antiviral factors discussed above, we did
find a substantial contribution of the type I-signaling network
to the IFN--induced refractory state. This raises the question
of how the type I IFN-signaling network can influence the
IFN- effect, when only minute amounts are transiently in-
duced in the system by IFN- alone.
It has become clear in the last few years that the IFN-
signaling pathways do not function independently and that
cross talk occurs between their constituent components (25, 52,
55, 67, 68, 78). One of the molecular mechanisms underlying
this is the priming of cells for type II stimuli by small amounts
of type I cytokines. This model was first described following
work in an encephalomyocarditis virus (EMCV) infection sys-
tem (77, 79). In this system, it has been demonstrated that type
I IFN signaling and constitutive subthreshold expression of
type I IFNs are necessary to mount a full protective IFN-
response in pretreated cells (Fig. 6). Further, IFN- constitu-
tively expressed prior to any stimulation with IFN- has been
shown to be necessary to maintain STAT1 levels for IFN-R1
blockage by antibodies, and it has been shown that depletion of
IFN- reduces STAT1 levels (25). In agreement with those
studies, reduced STAT1 and STAT2 levels have been reported
in IFN-R1/ and Tyk2/ BMDMs (39, 75, 76). Further-
more, in the study by Zimmermann et al. (2005), it was shown
that IFN-/ contributes to an IFN--induced refractory state
in MEFs and that MCMV counteracts this mechanism through
the virus-encoded factor M27. This viral protein triggers the
FIG. 6. Schematic model of the cross talk between type I and type
II signaling. The constitutive subthreshold expression of type I IFNs is
mediated by c-Jun binding to the IFN- enhancer (25) but is not
triggering a full-scale type I response. Binding of subthreshold levels of
type I IFNs by their cognitive receptor leads to low-level expression of
type I-stimulated genes and is necessary to maintain expression levels
of STAT1. A functional role for STAT2 in this system has been dem-
onstrated (85), although it is not clear if ISGF3 is involved in the
constitutive autocrine loop. Type I signaling mainly functions through
ISGF3 activation but can also directly activate STAT1 homodimers,
which in turn could induce expression of the STAT1 gene. This primes
cells for the secondary IFN- signal, increasing sensitivity for extracel-
lular IFN- levels. The IFN- signal then induces the expression of
several hundred target genes, establishing an antiviral state. Some of
the induced genes, namely, MDA-5, TBK1, TANK, IRF1, IRF7, and
IRF8, are components of IFN--inducing pathways, therefore proba-
bly facilitating the observed transient expression of IFN- by IFN-.
This transient induction provides an additional feedback loop in the
system, temporarily amplifying the constitutive autocrine loop and
probably further increasing the levels of STAT1. If the functionality of
the constitutive type I autocrine loop is impaired, levels of STAT1 are
reduced and the system will be less responsive to the secondary IFN-
signal.
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degradation of STAT2, a component of the ISGF3 complex
and an element of the type I-signaling cascade (85).
In the work presented here, we provide evidence that a
functional type I-signaling pathway is essential for establishing
a full antiviral state in IFN--treated BMDMs and that the
contribution of type I IFNs is necessary for this mechanism. In
this regard, it is notable that the amount of IFN- that was
induced by pretreatment with IFN- alone is small compared
to the amount of IFN- induced by the infection process itself.
Further, we could not detect a full type I response in IFN--
pretreated cells, indicating that the IFN- concentration was
below a threshold required to trigger a type I-induced antiviral
state alone. These results suggest that the induced IFN- in
our system is unlikely to be directly triggering the antiviral
state induced by IFN-. The possibility that the small amounts
of IFN- further amplify the constitutive priming levels of IFN
type I in BMDMs is viable. We recognize, however, that the
IFN-R1/, IFN-1/, and Tyk2/ BMDMs used in this
study do not allow us to completely determine the role of
IFN- in our system. The type I-deficient BMDMs have been
shown to be more permissive for viral replication than WT
BMDMs. It is therefore possible that the IFN--induced ef-
fects are insufficient to complement the loss of a functional
type I system at low levels. Furthermore, we cannot formally
exclude the possibility that the inability to induce IFN- after
infection with MCMV is influencing the IFN--induced phe-
notype. Significantly, however, we could still detect induction
of an antiviral state in the type I-deficient BMDMs by IFN-.
Overall, the results reported here are consistent with the
more recently refined EMCV model described above (25),
although we do detect minute quantities of IFN- in our sys-
tem. However, these levels are unlikely to directly cause the
antiviral state but could further amplify the sensitivity for an
IFN- stimulus. In this scenario, a transient induction of IFN-
expression could increase STAT1 levels further and by that
counteract desensitization of the system by induced inhibitors
of STAT activity (see the model in Fig. 6).
In the in vivo context, this mechanism probably contributes
significantly to the protective effects of IFNs for noninfected
bystander cells close to a focus of CMV infection or reactiva-
tion. In support of this, we demonstrated that type I signaling
is more important at low concentrations of IFN-. It is likely,
therefore, that it would play a more significant role in vivo,
where IFN- concentrations may occur at lower concentrations
than applied in our in vitro systems.
In summary, our findings demonstrate that type I IFNs make
a vital contribution to an IFN--induced block of viral repli-
cation in BMDMs and an early mechanism of this inhibition
involves a blockade of MIEP activity. Overall, this study pro-
vides further insights into the molecular mechanism of func-
tional cross talk between type I and type II IFNs in the
MCMV-macrophage system.
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